PMID- 29369972
OWN - NLM
STAT- MEDLINE
DCOM- 20181011
LR  - 20220330
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 102
IP  - 2S Suppl 1
DP  - 2018 Feb
TI  - mTOR Inhibition and Kidney Diseases.
PG  - S32-S40
LID - 10.1097/TP.0000000000001729 [doi]
AB  - Mammalian or mechanistic target of rapamycin (mTOR) is a serine-threonine kinase 
      that plays essential roles in cell growth, proliferation, metabolism, and 
      survival. Increased activation of the mTOR pathway is observed in patients and 
      animal models of renal transplant rejection, autosomal dominant polycystic kidney 
      disease, renal cell carcinoma, diabetic nephropathy, lupus nephritis, and 
      angiomyolipoma. Agents that inhibit mTOR, such as sirolimus and everolimus, are 
      incorporated in immunosuppressive regimens to prevent renal allograft rejection 
      and are often used to facilitate calcineurin inhibitor minimization or to reduce 
      the incidence of tumor recurrence. There are data from basic or animal studies to 
      suggest that sirolimus and its analogs may also benefit patients with autosomal 
      dominant polycystic kidney disease and metabolic- or immune-mediated renal 
      diseases through its ability to reduce glomerular hypertrophy, renal parenchymal 
      inflammation and fibrosis, but translation into clinical use has proved 
      challenging. This review summarizes the current understanding of mTOR signaling 
      pathway under physiological and pathological conditions and recent findings on 
      mTOR inhibitors in the management of kidney transplantation and nontransplant 
      kidney diseases.
FAU - Ma, Maggie K M
AU  - Ma MKM
AD  - Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong 
      Kong.
FAU - Yung, Susan
AU  - Yung S
AD  - Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong 
      Kong.
FAU - Chan, Tak Mao
AU  - Chan TM
AD  - Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong 
      Kong.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Everolimus/*therapeutic use
MH  - Graft Rejection/*prevention & control
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Kidney Diseases/*drug therapy/surgery
MH  - *Kidney Transplantation
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Sirolimus/*therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
MH  - Treatment Outcome
EDAT- 2018/01/26 06:00
MHDA- 2018/10/12 06:00
CRDT- 2018/01/26 06:00
PHST- 2018/01/26 06:00 [entrez]
PHST- 2018/01/26 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
AID - 00007890-201802001-00007 [pii]
AID - 10.1097/TP.0000000000001729 [doi]
PST - ppublish
SO  - Transplantation. 2018 Feb;102(2S Suppl 1):S32-S40. doi: 
      10.1097/TP.0000000000001729.